DNM1L and carcinoma: Although depletion of DRP1 (27, 58, 59) or its adaptor protein MFF (25, 26) has been shown to suppress drug resistance in carcinomas, stable DRP1 knockdown did not mitigate drug resistance in our sarcoma models (Figs 5, S10, and S11).